BioSpace News Archive

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced the pricing of its private offering of $250 million aggregate principal amount of 2.75% Convertible Senior Notes due 2027.

Replimune Group, Inc., a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced the pricing of its public offering of 2,826,088 shares of its common stock at a public offering price of $23.00 per share.

Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) is pleased to announce that it has obtained TSX-V approval to issue 16,760,000 common shares of the Company to settle outstanding debt.

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic

KN026 is an anti-HER2 bispecific antibody which can simultaneously bind two non-overlapping epitopes of HER2 and lead to a dual HER2 signal blockade, presumedly causing HER2 to aggregate on the cell surface and endocytose.

Eyenuk, Inc. and Devlyn Optical, a spin-off of Grupo Devlyn, a multinational optical retailer with over one thousand stores in Mexico, Guatemala, El Salvador, and the USA, announced that they will collaborate to pilot diabetic retinopathy screening services at Devlyn’s convenient optical retail locations by leveraging Eyenuk’s AI-enabled DR screening and telemedicine technologies.

Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, Cancer Research UK and Cambridge University Hospitals NHS Foundation Trust, announce a collaboration to identify and develop microbiome co-therapeutics and biomarkers for cancer patients receiving immune checkpoint inhibitor therapy.

The Canadian Medical Association released a national poll showing that Canadians are embracing virtual care options and would like to see them not only continued after the COVID-19 crisis subsides but improved and expanded in the future.

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, announced that it has selected development candidate, IDE397, for its Methionine adenosyltransferase 2a Synthetic Lethality program.

The Biotechnology Innovation Organization released new data on the bioscience industry in the United States.